OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance

OS Therapies laid out a dense regulatory calendar for OST-HER2 in metastatic osteosarcoma: interim 3-year overall survival data plus an FDA Type C Statistical Methods meeting and an MHRA Statistical Methods Scientific Advice meeting are all expected in September 2026. RMAT and Rolling Review decisions are expected to follow the FDA meeting, with final 3-year overall survival data, a Pre-BLA meeting, a U.S. BLA submission under the Accelerated Approval Program, and CMAA submissions in Europe, the U.K., and Australia slated for Q4 2026.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.